

SCOLR Pharma, Inc.  
Form 8-K  
November 12, 2004

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 12, 2004

**SCOLR Pharma, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

000-24693  
(Commission File Number)

91-1689591  
(IRS Employer  
Identification No.)

3625 132nd Avenue SE  
Suite 300  
Bellevue, Washington 98006  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (425) 373-0171

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4 (c))
- 
- 
-

***Item 2.02 Results of Operations and Financial Condition.***

On November 12, 2004, SCOLR Pharma, Inc. announced its third quarter 2004 financial results. A copy of the press release containing the announcement is attached as Exhibit 99.1. The information in this Current Report is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SCOLR, INC.**

November 12, 2004

By: /s/ Daniel O. Wilds

\_\_\_\_\_  
Daniel O. Wilds  
President and Chief Executive Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of SCOLR Pharma, Inc. dated November 12, 2004